Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook

Date: October 22, 2009
Pages: 141
Price:
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: IBCBBA69775EN
Leaflet:

Download PDF Leaflet

Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook
Despite public policy measures to prevent cancer, such as tobacco control and vaccination against HPV, cancer is sure to remain a significant public health problem throughout the 21st century. Indeed, the global demographic shift towards an ageing population and the spread of high tech modern medicine throughout the emerging economies of Asia and (maybe later) Africa, will expand the market for cancer diagnostics globally. Major developments are likely in both the IVD market and in imaging-based modalities, like computed tomography, with the emphasis being upon the personalized medicine approach, where demand will come from physicians, patients and payors – all of whom want more effective treatments and value for money.

This report analyzes the latest innovations in oncology diagnostics and identifies the most exciting new technologies and trends, ranging from body imaging and cytology to molecular diagnostics and pharmacogenomics. The report also identifies the key challenges facing innovative diagnostics companies.

Key Features of this report
  • Analysis the latest innovations in diagnostics imaging in the oncology sector, covering Magnetic Resonance Imaging (MRI), x-ray, Computed Tomography (CT), ultrasound, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Flow Cytometry.
  • Analyzes the latest innovations in molecular diagnostics and how they impact the diagnostics market. The report covers technology including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), HPV testing, immunoassays & biomarkers, microarrays and comparative genomic hybridization (CGH).
  • Analyzes the latest innovations in pharmacogenomics and covers the major applications for familial cancer, breast cancer, colon cancer and lung cancer. Also, the report provides an overview of the regulatory and intellectual property environment for genetic-based tests.
  • Looks at the key commercial challenges for innovative diagnostics companies, including the impact of the recession, reimbursement, regulatory changes, pharmacoeconomics and the relationship between industry and academia.

The report Includes in-depth case studies on the potential technologies available in core areas of un-met need such as ovarian cancer and colorectal cancer.

Key Benefits of this report
  • Understand the latest innovations in the oncology diagnostics market in the core areas – diagnostic imaging, molecular diagnostics and pharmacogenetics. This includes market information and an analysis of the scientific literature so as to identify what is really innovative.
  • Identify what the key areas of unmet need are in the oncology diagnostics market and understand which products have the greatest potential over the next decade.
  • Understand what the greatest challenges are for oncology diagnostics and what the best strategies are for coping with these obstacles.
  • Understand the competitive landscape and what companies are leading the way in terms of innovation, and what the latest partnerships regarding companion diagnostics.
  • Business Insights has identified five key areas of innovation in the diagnostics markets, use this to help guide company strategy.

Key findings from this report

Molecular diagnostics and biomarkers are the key drivers of the oncology diagnostics market.

Despite the deep economic recession, R&D spending has held up for oncology diagnostics companies. However, M&A activity has been impacted with the value of deals conducted in 2009 far below the peak year of 2007.

Partnerships between diagnostic firms and pharmaceutical firms represents the future of the industry and the number of companion deals has been increasing in the past few years.

Virtual colonoscopy - using CT scans to build a picture of the colon - is becoming an increasingly accepted alternative to invasive colonoscopy for colorectal screening in high risk groups and the general population. This presents a sizeable market opportunity.

Interesting research is being conducted in both ovarian cancer and for prostate cancer, which could have wide-market implications. Specifically, companies are looking to validate new biomarkers to create more accurate tests.

Key questions answered by this report
  • What is the market potential for in vitro diagnostic products?
  • What is the market forecast for oncology diagnostics?
  • What are the key innovations in diagnostic testing and diagnostic imaging?
  • What are the major areas of unmet need in oncology diagnostics?
  • What are the most promising technology areas in oncology diagnostics, and which companies are exploiting these?
  • What will be the key trends impacting the market in the long-term?
  • How can big pharma fully exploit the opportunities in the oncology diagnostics sector?
Innovations in oncology diagnostics
Executive summary
Setting the scene
Innovations in diagnostic imaging
Innovations in molecular diagnostics
Innovations in pharmacogenomics
Challenges in the oncology diagnostics sector
Competitive landscape

CHAPTER 1 SETTING THE SCENE

Summary
Introduction
Cancer facts, current and projected
History of oncology diagnostics
Elements of a cancer diagnosis
Pathology
Oncology diagnostics market

CHAPTER 2 INNOVATIONS IN DIAGNOSTIC IMAGING

Summary
Introduction
Body imaging
Overview
X-ray
Breast cancer
Computed tomography
Lung cancer
Colon cancer
Others
Ultrasound
Magnetic resonance imaging
Nuclear medicine – PET & SPECT
Case study
HYPERImage
Cytology
Overview
Flow cytometry
Case study
CellSearch
Cervical screening
Cytogenetics

CHAPTER 3 INNOVATIONS IN MOLECULAR DIAGNOSTICS

Summary
Introduction
DNA, genes and chromosomes
Fluorescence in situ hybridization (FISH)
PCR and variants
Case study
HPV testing
Immunoassays and biomarkers
Case study
Ovarian cancer
PSA testing
Other areas of research
Epigenomics
Microarrays
Comparative genomic hybridization (CGH)
Case study
Almac
DiaGenic
Overview of clinical applications of molecular diagnostics
BCR-ABL
LOH
MSI

CHAPTER 4 INNOVATIONS IN PHARMACOGENOMICS

Summary
Introduction
Familial cancer
Breast cancer
Colon cancer
Melanoma
Case study
IP challenge
Response to therapy
Cytochrome P450 variants
HER2 overexpression
The FDA, EMEA and PGx labeling
Case study
TheraScreen: KRAS
BioTheranostics: Breast cancer
Clarient: Breast cancer
Marker validation for erlotinib in lung cancer
Companion diagnostics

CHAPTER 5 CHALLENGES IN THE ONCOLOGY DIAGNOSTICS SECTOR

Summary
Introduction
Reimbursement funding
Educated patients = educated decisions
Regulation
Pharmacoeconomics
Emerging markets
Partnerships between drug companies & academia
Research & development
Mergers & acquisitions

CHAPTER 6 COMPETITIVE LANDSCAPE

Summary
Introduction
Abbot Diagnostics
Affymetrix
Beckman Coulter
Becton Dickinson
Bio-Rad Laboratories
Gen-Probe
Johnson & Johnson (J&J)
Ortho Clinical Diagnostics
Luminex
Tm Bioscience
Nanogen
Roche Diagnostics
Siemens Healthcare Diagnostics
Sysmex
Future perspectives in the oncology diagnostics market
Science
Infrastructure
Adoption of innovation
Companion diagnostics

CHAPTER 7 APPENDIX

Glossary
Index

LIST OF FIGURES

Figure 1.1: Leading sites of new cancer US, 2009
Figure 1.2: Leading sites of new cancer in developing countries, 2007
Figure 1.3: Information required by oncologist pre/post diagnosis
Figure 1.4: Oncology diagnostics forecasts ($bn), 2007-14
Figure 2.5: Example of the use of 3D tomosynthesis imaging
Figure 2.6: Number of CT scans in the US, 1995-2008
Figure 2.7: Women having mammograms (%) in the US, 2004*
Figure 2.8: Global flow cytometry market forecast ($bn), 2008-14
Figure 3.9: IV diagnostics market forecast ($bn), 2007-2014)
Figure 3.10: Use of biomarkers
Figure 3.11: Obstacles to biomarker development
Figure 3.12: US 5-year survival (%) for ovarian cancer at time of diagnosis
Figure 4.13: Myriad: Molecular diagnostics sales ($m), 2005-09
Figure 4.14: Number of biologics regulated by CDER that have existing PGx information
Figure 4.15: Herceptin therapy cost ($) per patient relative to HER2 testing
Figure 5.16: Decline in S&P global sector indices (%), 12 months to December 2008
Figure 5.17: IV diagnostics risk-based classification
Figure 5.18: FDA validated biomarkers by therapeutic area, September 2009
Figure 5.19: Roche Diagnostics regional sales (CHFm), 2008
Figure 5.20: Leading diagnostic firms increase in R&D spend (%) y-o-y, 2008

LIST OF TABLES

Table 1.1: WHO cancer mortality forecasts by region (‘000), 2008-30
Table 1.2: In vitro diagnostics market forecast ($bn), 2008-14
Table 2.3: Overview of imaging systems
Table 2.4: Mortality reduction (%) attributed to FOBT screening, 1985-96
Table 2.5: Organ radiation data from various clinical studies
Table 3.6: Extensively investigated cancer biomarkers
Table 3.7: Market potential for Epigenomics’ cancer specialty tests
Table 4.8: Absent/incomplete efficacy (%) of drugs by therapeutic class
Table 5.9: Leading M&A deals in the diagnostics industry ($m), 2009
Table 6.10: Sales for the leading innovative oncology diagnostics companies ($m), 2006-08
Table 6.11: Beckman Coulter R&D investment ($m), 2004-08
Table 6.12: Bio-Rad sales ($bn) 2004-2008
Table 6.13: Roche Diagnostics sales by division (CHFm), H109
Table 6.14: Major recent Dx-Rx partnerships
Skip to top


Ask Your Question

Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: